FIGURE

Fig. 1

ID
ZDB-FIG-220722-3
Publication
Rusnati et al., 2021 - Cholenic acid derivative UniPR1331 impairs tumor angiogenesis via blockade of VEGF/VEGFR2 in addition to Eph/ephrin
Other Figures
All Figure Page
Back to All Figure Page
Fig. 1

Binding of UniPR1331 to VEGFR2.

a Chemical structure of UniPR1331. b SPR sensorgrams showing the binding of UniPR1331 (40 μM) to the VEGFR2-Fc-coated or to the control Fc-coated surfaces. c Blank-subtracted SPR sensorgrams derived from injection of UniPR1331 on the VEGFR2-Fc surface. d Steady-state analysis obtained by Scatchard’s plot analysis of the bound RU values at equilibrium from b. White dot represents UniPR1331 binding to a control VEGF-coated surface. e ELISA-based competition experiments: inhibition curves of the binding of biotinylated ephrin-A1-Fc or VEGF to immobilized EphA2-Fc and VEGFR2 ectodomain by UniPR1331. Data in bd are representative of other three experiments that gave similar results. Data in e are expressed as percent of binding in respect to control without inhibitor and are the mean ∓ S.E.M. of 3–6 independent experiments. f Modeled structure of the UniPR1331/VEGFR2 complex from the final frames of MD showing the key residues involved in the interaction. D2–D3 domain of VEGFR2 is depicted in white cartoons representations. VEGFR2 residues involved in the interaction and UniPR1331 are shown in gray and magenta sticks (oxygen in red, nitrogen in blue). Hydrophilic (H-bonds and salt links) and hydrophobic interactions are indicated with yellow dashed and green dotted lines.

Expression Data

Expression Detail
Antibody Labeling
Phenotype Data

Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Cancer Gene Ther.